Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 3 % of short-term debt in 2025; threshold 65 %.
-
Not on Peppol Peppol
Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.
Financials
Financial year 2025
SOCIETE BELGE ET EUROPEENNE DE RECHERCHES ET D'APPLICATIONS MEDICALES from Oupeye, company number BE0417814038, closed financial year 2025 with a result of € -2,450 after tax. For that financial year SOCIETE BELGE ET EUROPEENNE DE RECHERCHES ET D'APPLICATIONS MEDICALES recorded a gross margin of € -486 and equity of € 54,492. Compared with financial year 2024, the result moved from € -24,893 to € -2,450. The company made a loss. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 2, 2026.
€ 54,492
▼ 4% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -2,450
▲ 90 % less loss than in 2024
Profit after tax over the fiscal year.
€ 5,408
▲ € 4,532 vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 35,900.
People and assets in 2025
€ 1,466
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 700
▼ 86% vs 2024
Loans from banks and other lenders, long and short.
€ 171
▼ 21% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -641 | € 4,668 | € -809 | € -486 | ▲ € 323 |
| Profit after taxes | € -14,003 | € -4,289 | € -24,893 | € -2,450 | ▲ € 22,443 |
| Equity | € 86,123 | € 81,834 | € 56,941 | € 54,492 | ▼ 4% |
| Total debts | € 187,236 | € 182,147 | € 178,728 | € 172,637 | ▼ 3% |
| Cash | € 1,919 | € 11,470 | € 875 | € 5,408 | ▲ € 4,532 |
| Retained profit | € 67,531 | € 63,242 | € 38,349 | € 35,900 | ▼ 6% |
| Bank debt | € 50,692 | € 42,661 | € 4,848 | € 700 | ▼ 86% |
| Balance sheet total | € 273,359 | € 263,981 | € 235,669 | € 227,128 | ▼ 4% |
Key figures of SOCIETE BELGE ET EUROPEENNE DE RECHERCHES ET D'APPLICATIONS MEDICALES, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to SOCIETE BELGE ET EUROPEENNE DE RECHERCHES ET D'APPLICATIONS MEDICALES?
What happened at SOCIETE BELGE ET EUROPEENNE DE RECHERCHES ET D'APPLICATIONS MEDICALES in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 2,450. Source: NBB ↗
- Nelly DELDINNE became a director. NBB
- Start of the company according to the CBE. KBO
- New establishment in Bassenge. KBO
In short
From € 14,003 loss in 2022 to € 2,450 loss in 2025.
Paid € 670 in corporate taxes since 2022.
A new publication or filing at SOCIETE BELGE ET EUROPEENNE DE RECHERCHES ET D'APPLICATIONS MEDICALES? We notify you, reason included.
Follow SOCIETE BELGE ET EUROPEENNE DE RECHERCHES ET D'APPLICATIONS MEDICALESDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind SOCIETE BELGE ET EUROPEENNE DE RECHERCHES ET D'APPLICATIONS MEDICALES are JACQUY PIRARD and Nelly DELDINNE. It owns 49.8% of PIDEL itself.
Directors
According to the 2025 annual accounts
Nelly DELDINNE
Director
since 2013
Establishments
Establishment units
Physical locations of this company
Rue du Roi Albert 158b
4680 Oupeye
Rue Bettonville 5
4690 Bassenge
Active since 1 July 1977
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0417.814.038
- VAT number
- BE 0417.814.038
- Registered office
- Rue du Roi Albert 158b, 4680 Oupeye
- Names & denominations
- SOCIETE BELGE ET EUROPEENNE DE RECHERCHES ET D'APPLICATIONS MEDICALES · SOBERAM
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 28 November 1977
- Peppol
- Not registered